Latest:
Exploring the Nuances of Postoperative Considerations in Pancreatic Cancer
Zyed Nabeel Zafar, MD, MPH, explores the nuances of postoperative considerations in pancreatic cancer treatment.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Narjust Florez, MD
Narjust Florez, MD, is the associate medical director of the Cancer Care Access Program and a thoracic medical oncologist at the Dana-Farber Cancer Institute in Boston, Massachusetts.
Latest:
Reviewing Key Data in Resectable and ROS1+ NSCLC With Drs Florez and Sabari
Narjust Florez, MD, and Joshua K. Sabari, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
J.Thaddeus Beck, MD, FACP
J.Thaddeus Beck, MD, FACP is a medical oncologist at Highlands Oncology located in Rogers, Arkansas.
Latest:
FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP
J. Thaddeus Beck, MD, FACP, about the FDA approval of subcutaneous pembrolizumab.
Jian Zhang, MD
Jian Zhang, MD, is a professor at Fudan University Shanghai Cancer Center in China.
Latest:
Dr Zhang on the Rationale of Evaluating SIM0270/Everolimus in ER+/HER2– Advanced Breast Cancer
Jian Zhang, MD, details the rationale of evaluating SIM0270 plus everolimus in patients with ER-positive/HER2-negative advanced breast cancer.
Benjamin L. Maughan, MD, PharmD
Benjamin L. Maughan, MD, PharmD, is an associate professor in the Division of Medical Oncology at Huntsman Cancer Institute of University of Utah Health.
Latest:
Dr Maughan on the Need for Consensus on Treatment Intensification in mHSPC
Benjamin L. Maughan, MD, PharmD, discusses the need for improved update of treatment intensification in metastatic hormone-sensitive prostate cancer.
Collin Blakely MD, PhD
Latest:
Dr Blakely on the Rationale for Investigating Neoadjuvant Osimertinib in EGFR-Mutated NSCLC
Collin Blakely, MD, PhD, discusses a phase 2 trial evaluating the use of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutated non-small cell lung cancer, findings from which were presented at the 2023 ASCO Annual Meeting.
Yang Xia, MD, PhD
Yang Xia, MD, PhD, is an associate professor in the Department of Respiratory Medicine at the Second Affiliated Hospital Zhejiang University School of Medicine.
Latest:
Dr Xia on the Differences Between ctDNA Monitoring Strategies in MET Exon 14–Mutant NSCLC
Yang Xia, MD, PhD, discusses the use of different ctDNA monitoring to detect resistance and predict outcomes in NSCLC with MET exon 14 skipping mutations.
Julia S. Wong, MD,
Latest:
Dr Wong on Hypofractionation vs Conventional Fractionation in Breast Cancer Postmastectomy
Julia S. Wong, MD, discusses findings from data presented on patient-reported toxicity results from the randomized trial of fractionation following breast reconstruction in patients with breast cancer.